NCT07470814: AMICS-Reg

Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock

Not yet recruiting Last updated 13 March 2026

What this trial tests

trial in Acute Myocardial Infarction Complicated With Cardiogenic Shock in 1,000 participants. Not yet recruiting.

Timeline

15 April 2026

Primary endpoint
15 April 2029

15 July 2029

Quick facts

Lead sponsor	Beijing Anzhen Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	15 April 2026
Primary completion	15 April 2029
Estimated completion	15 July 2029

Conditions studied

• Acute Myocardial Infarction Complicated With Cardiogenic Shock — all drugs for Acute Myocardial Infarction Complicated With Cardiogenic Shock →

Sponsor

Beijing Anzhen Hospital

Who can join

18 and older, any sex, with Acute Myocardial Infarction Complicated With Cardiogenic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) represents the most life-threatening subtype of acute cardiovascular diseases. Current clinical management of AMI-CS in China is plagued by multiple structural challenges, including a rapidly aging patient population, inequitable distribution of medical resources, the absence of standardized care models, and poor applicability of international risk stratification tools. Owing to ethnic disparities in disease presentation and the low penetration of mechanical circulatory support (MCS) devices in China, international clinical evidence for AMI-CS diagnosis and treatment cannot be directly translated into local clinical practice. Furthermore, the lack of a standardized multidisciplinary collaborative care system has become a critical bottleneck hindering the reduction of AMI-CS mortality. To address these unmet clinical needs, this study aims to develop a tailored multidisciplinary collaborative care system adapted to China's healthcare landscape and to evaluate its clinical efficacy and safety via a prospective multicenter registry study. The study will establish a tiered collaborative network encompassing healthcare institutions of all levels and formulate standardized clinical pathways and risk stratification strategies for AMI-CS. A total of at least 1,000 AMI-CS patients will be enrolled in the study, with systematic collection of their clinical characteristics, multidisciplinary interventions, MCS utilization, and prognostic outcomes to build a high-quality real-world database. Based on the registry data, a China-specific risk stratification model for AMI-CS will be developed by integrating clinical metrics, biomarkers, and imaging features. This study will assess the benefits and risks of MCS devices used alone or in combination, and evaluate the implementation effectiveness of the multidisciplinary collaborative care system by comparing core outcomes-including 30/180-day all-cause mortality, severe complication rates, and door-to-balloon times-before and after the system's rollout and across healthcare institutions of different tiers. Additionally, this study will explore the key factors influencing the efficacy of multidisciplinary collaboration to inform the optimization of the care system. This study is expected to validate the feasibility and effectiveness of the multidisciplinary collaborative care system in the Chinese clinical setting, reduce AMI-CS mortality, narrow the gap in care capacity across different-tier hospitals, and fill the evidence gap in multidisciplinary AMI-CS management for the Chinese population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.